Following on from information provided to NICE by the company in March 2011, the appraisal of Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 333
Referral date 01 April 2010
Topic area
  • Musculoskeletal

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Tonya Gillis
Executive Lead: Andrew Dillon
Project manager: Jeremy Powell
Technical Lead: Whitney Miller

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in March 2011, the appraisal of Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
22 March 2011

The manufacturer has informed us that they will not be seeking a license for this particular indication at the present time.

NICE has therefore decided to suspend this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.”


For further information on our processes and methods, please see our CHTE processes and methods manual